Newest Patent for Biological Signal Management
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Oct. 28, 2009--
CardioNet, Inc. (NASDAQ: BEAT) announced today that the U.S. Patent and
Trademark office has granted patent number 7,587,237 (“Biological Signal
Management”) to CardioNet. The patent includes certain systems and
techniques utilized by the Company’s Mobile Cardiac Outpatient
Telemetry™ (MCOT™) system that automatically processes complex
physiological information to make it useful for clinical decisions. This
is the 15th U.S. Patent that has been issued to CardioNet.
Randy Thurman, CardioNet Chairman, President and CEO, commented, “A key
to success in delivering wireless medicine is rooted in our ability to
distill the wide variety of information collected from sensors on the
body and make that data useful for clinicians or other healthcare
providers. With MCOT™, we provide electrocardiogram and trended heart
rate data to physicians in order for them to make clinically relevant
decisions. The issuance of this patent demonstrates our continued focus
on innovation for applications in wireless medicine. Establishing and
defending our extensive patent portfolio is key to our long-term
strategy. This newly issued patent reinforces CardioNet’s position as
the pioneer and technology leader in mobile cardiac outpatient
telemetry.”
The issued patent abstract states: Systems and techniques for managing
biological signals. In one implementation, a method includes receiving a
cardiac biological signal that includes information describing events,
determining a merit of each event based on one or more of a severity of
a cardiac condition associated with the event and a quality of the
event, and handling a subset of the events that meet a merit criterion.
The subset can be handled for medical purposes.
About CardioNet
CardioNet is the leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely
clinical information regarding an individual's health. CardioNet's
initial efforts are focused on the diagnosis and monitoring of cardiac
arrhythmias, or heart rhythm disorders, with a solution that it markets
as Mobile Cardiac Outpatient Telemetry™ (MCOT™). More information can be
found at http://www.cardionet.com.
Forward Looking Statements
This press release includes certain forward-looking statements within
the meaning of the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995 regarding, among other things, our growth
prospects, the prospects for our products and our confidence in the
Company's future. These statements may be identified by words such as
"expect," "anticipate," "estimate," "intend," "plan," "believe,"
"promises" and other words and terms of similar meaning. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including important factors that could
delay, divert, or change any of them, and could cause actual outcomes
and results to differ materially from current expectations. These
factors include, among other things, the success of our sales and
marketing initiatives, our ability to attract and retain talented
executive management and sales personnel, our ability to identify
acquisition candidates, acquire them on attractive terms and integrate
their operations into our business, the commercialization of new
products, market factors, internal research and development initiatives,
partnered research and development initiatives, competitive product
development, changes in governmental regulations and legislation,
changes to reimbursement levels for our products, the continued
consolidation of payors, acceptance of our new products and services and
patent protection and litigation. For further details and a discussion
of these and other risks and uncertainties, please see our public
filings with the Securities and Exchange Commission, including our
latest periodic reports on Form 10-K and 10-Q. We undertake no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events, or otherwise.
Source: CardioNet, Inc.
CardioNet, Inc.
Marty Galvan, 800-908-7103
Investor Relations
investorrelations@cardionet.com
